Drug Details
| General Information of the Drug (ID: DR3243) | ||||
|---|---|---|---|---|
| Name |
Clofarabine
|
|||
| Synonyms |
CAFdA; CFB; Clofarabina; Clofarabinum; Clofarex; Clolar; Evoltra; Clofarabine [USAN]; Clolar (TN); Evoltra (TN); Clofarabine (USAN/INN); Clolar, Evoltra, Clofarabine; Cl-F-Ara-A; (2R,3R,4S,5R)-5-(6-amino-2-chloropurin-9-yl)-4-fluoro-2-(hydroxymethyl)oxolan-3-ol; 2-Chloro-9-(2-deoxy-2-fluoro-b-D-arabinofuranosyl)-9H-purin-6-amine; 2-Chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-9H-purin-6-amine; 2-Chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)adenine; 2-Cl-2'-F-araA; 2-chloro-9-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)adenine; 3S211048
Click to Show/Hide
|
|||
| Molecular Type |
Small molecule
|
|||
| Disease | Myelodysplastic syndrome [ICD-11: 2A37] | Approved | [1] | |
| Structure |
|
Click to Download Mol2D MOL |
||
| Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | ||||
| Formula |
C10H11ClFN5O3
|
|||
| PubChem CID | ||||
| Canonical SMILES |
C1=NC2=C(N=C(N=C2N1C3C(C(C(O3)CO)O)F)Cl)N
|
|||
| InChI |
1S/C10H11ClFN5O3/c11-10-15-7(13)5-8(16-10)17(2-14-5)9-4(12)6(19)3(1-18)20-9/h2-4,6,9,18-19H,1H2,(H2,13,15,16)/t3-,4+,6-,9-/m1/s1
|
|||
| InChIKey |
WDDPHFBMKLOVOX-AYQXTPAHSA-N
|
|||
| CAS Number |
CAS 123318-82-1
|
|||
| TTD Drug ID | ||||
| DrugBank ID | ||||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug | ||||||
| Resveratrol | Gnetum parvifolium | Click to Show/Hide the Molecular Data of This NP | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [2] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Phosphorylation | AKT1 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | CCND1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | CDKN1A | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | MET | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | PSG1 | Molecule Info | |||
| In-vitro Model | MeT-5A | CVCL_3749 | Healthy | Homo sapiens | ||
| MSTO-211H | CVCL_1430 | Pleural biphasic mesothelioma | Homo sapiens | |||
| Experimental
Result(s) |
The synergistic antiproliferative effect of resveratrol and clofarabine is linked to the inhibition of Akt and Sp1 activities. | |||||
| Sulforaphane | Brassica oleracea | Click to Show/Hide the Molecular Data of This NP | ||||
| Augmenting Drug Sensitivity | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [3] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Expression | CDKN2A | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | MCF-7 | CVCL_0031 | Invasive breast carcinoma | Homo sapiens | ||
| MDA-MB-231 | CVCL_0062 | Breast adenocarcinoma | Homo sapiens | |||
| Experimental
Result(s) |
Clofarabine in combination with sulforaphane significantly reactivates DNA methylation-silenced CDKN2A tumour suppressor and inhibits cancer cell growth at a non-invasive breast cancer stage. | |||||
| Target and Pathway | ||||
|---|---|---|---|---|
| Target(s) | Bacterial Penicillin binding protein (Bact PBP) | Molecule Info | [4] | |
| Ribonucleotide reductase (RIR) | Molecule Info | [4] | ||
